Studies performed during the past 2 years have provided a deeper understanding into the role of CTLA-4, which is expressed ... additional peripheral regulatory mechanisms ensure that the ...

针对程序性细胞死亡蛋白1(PD-1)和细胞毒性T淋巴细胞相关蛋白4(CTLA-4)的免疫检查点抑制剂已经彻底改变了黑色素瘤患者的治疗方法。基于早期对其 ...

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology innovation, today highlights key scientific contributions in 2024-2025 that are shaping the future of cancer immunotherapy.

Among 13,568 patients with malignant melanoma, 145 were treated with PD1 inhibitors and 212 were treated with the CTLA-4 inhibitor ipilimumab. One year after starting treatment, 6.6% and 7.5% ...

BAY43-9006 (Sorafenib) Small-molecule inhibitor BRAF, EGFR ... Blocking monoclonal antibody CTLA-4 Phase III Ipilimumab Blocking monoclonal antibody CTLA-4 Phase II MDX-1106 Blocking monoclonal ...